U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07641036) titled 'Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer' on June 06.
Brief Summary: This example phase 1/2, open-label, biomarker-selected study evaluates EB-HC01, an allogeneic dual-target CARNK product composed of a 1:1 mixture of HER2-CAR-NK and CEACAM5-CAR-NK cells, in adults with unresectable or metastatic cholangiocarcinoma or other biliary tract cancers after standard therapy. Part A determines safety, dose-limiting toxicities (DLTs), and the recommended phase 2 dose (RP2D) after reduced-intensity lymphodepletion. Part B evaluates preliminary anti-tumor activity, CAR-NK persistence, and biomarker-response associati...